Harel Insurance Investments & Financial Services Ltd. Has $122,000 Holdings in Celgene Corporation (CELG)

Harel Insurance Investments & Financial Services Ltd. continued to hold its stake in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 942 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Celgene Corporation were worth $122,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in CELG. Waldron LP lifted its holdings in shares of Celgene Corporation by 48.9% in the first quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock valued at $640,000 after buying an additional 1,709 shares during the period. Beaumont Financial Partners LLC lifted its holdings in shares of Celgene Corporation by 7.2% in the first quarter. Beaumont Financial Partners LLC now owns 12,530 shares of the biopharmaceutical company’s stock valued at $1,559,000 after buying an additional 840 shares during the period. Swedbank lifted its holdings in shares of Celgene Corporation by 4.5% in the first quarter. Swedbank now owns 2,595,776 shares of the biopharmaceutical company’s stock valued at $322,992,000 after buying an additional 111,818 shares during the period. North Star Investment Management Corp. lifted its holdings in shares of Celgene Corporation by 6.6% in the first quarter. North Star Investment Management Corp. now owns 27,230 shares of the biopharmaceutical company’s stock valued at $3,388,000 after buying an additional 1,680 shares during the period. Finally, Macguire Cheswick & Tuttle Investment Counsel LLC lifted its holdings in shares of Celgene Corporation by 2.6% in the first quarter. Macguire Cheswick & Tuttle Investment Counsel LLC now owns 92,374 shares of the biopharmaceutical company’s stock valued at $11,494,000 after buying an additional 2,370 shares during the period. Institutional investors and hedge funds own 79.36% of the company’s stock.

CELG has been the subject of several research analyst reports. Bank of America Corporation restated a “buy” rating and issued a $153.00 price objective on shares of Celgene Corporation in a report on Monday, July 10th. SunTrust Banks, Inc. set a $150.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Credit Suisse Group set a $148.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Stifel Nicolaus restated a “buy” rating and issued a $139.00 price objective on shares of Celgene Corporation in a report on Thursday, July 6th. Finally, Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 6th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-two have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $150.60.

TRADEMARK VIOLATION WARNING: This report was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://sportsperspectives.com/2017/10/11/harel-insurance-investments-financial-services-ltd-has-122000-holdings-in-celgene-corporation-celg.html.

In related news, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now owns 76,301 shares in the company, valued at $10,264,010.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders have sold 46,233 shares of company stock worth $6,268,259 in the last quarter. 0.95% of the stock is currently owned by corporate insiders.

Celgene Corporation (NASDAQ:CELG) opened at 139.69 on Wednesday. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $147.17. The firm has a market capitalization of $109.29 billion, a price-to-earnings ratio of 43.26 and a beta of 1.88. The firm has a 50-day moving average price of $139.99 and a 200 day moving average price of $129.85.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the company posted $1.44 earnings per share. Celgene Corporation’s revenue was up 18.7% on a year-over-year basis. On average, equities analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply